Oncolytics Biotech Inc. (ONCY)
| Market Cap | 117.48M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -33.12M |
| Shares Out | 22.14M |
| EPS (ttm) | -0.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 21 |
| Last Price | $2.72 |
| Previous Close | $2.89 |
| Change ($) | -0.17 |
| Change (%) | -5.88% |
| Day's Open | 2.84 |
| Day's Range | 2.70 - 2.88 |
| Day's Volume | 1,039,441 |
| 52-Week Range | 0.98 - 4.03 |
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 817 13...
Oncolytics Biotech Inc. (ONCY) CEO Matt Coffey on Q3 2020 Results - Earnings Call Transcript
SAN DIEGO, and CALGARY, AB, Nov. 11, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and operational highlights for the quarter en...
- Conference call and webcast to take place on Wednesday, November 11, 2020 at 5:00 pm ET SAN DIEGO and CALGARY, AB, Nov. 6, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ...
SAN DIEGO and CALGARY, Alberta, Sept. 1, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc.
SAN DIEGO, Calif. and CALGARY, AB, Aug.
Oncolytics Biotech Inc. (ONCY) CEO Matt Coffey on Q2 2020 Results - Earnings Call Transcript
SAN DIEGO and CALGARY, Alberta, June 25, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced a new investigator-sponsored triple-negative breast cancer (TN...
SAN DIEGO, Calif. and CALGARY, Alberta, June 15, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-onc...
SAN DIEGO, California and CALGARY, Alberta, June 4, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today provided a recap of a Key Opinion Leader (KOL) call sponsored...
SAN DIEGO and CALGARY, Alberta, May 29, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic vi...
SAN DIEGO and CALGARY, Alberta, May 26, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic vi...
SAN DIEGO and CALGARY, Alberta, May 14, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic vi...
Oncolytics Biotech's (ONCY) CEO Matt Coffey on Q4 2019 Results - Earnings Call Transcript
During Q4 investors' call, Oncolytics (ONCY) is likely to provide an update on the studies of pelareorep, which is being developed for treating solid tumors and hematological malignancies.
While travel-related stocks were hit hard on concerns over coronavirus, experimental vaccine companies rallied.
Oncolytics Biotech: A Small But Very Promising Cancer Player In 2020
As of late, it has definitely been a great time to be an investor in Oncolytics.
About ONCY
Oncolytics Biotech, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negati... [Read more...]
| Industry Biotechnology | IPO Date Nov 8, 1999 |
| CEO Dr. Matthew C. Coffey | |
| Stock Exchange NASDAQ | Ticker Symbol ONCY |